Traws Pharma, Inc.: 5%+ holders

As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Traws Pharma, Inc. The largest reported stake is Orbimed Advisors LLC's, at 11.9%. 16 filings are on record since September 19, 2025 (Schedule 13D/A, May 5, 2026).

Squadron Master Fund LP also filed stake reports on 14 other companies ↓

Sell to companies like Traws Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 6,565,474 · Sole dispositive: 0 · Shared dispositive: 6,565,474 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 1,555,423 · Sole dispositive: 0 · Shared dispositive: 1,555,423 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Squadron Master Fund LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-12 · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 730,000 · Sole dispositive: 0 · Shared dispositive: 730,000 · SCHEDULE 13G/A, 2026-08-12
• Filed 2026-05-15 · Holder: Perceptive Advisors LLC · Percent: 6.1% · SCHEDULE 13G/A

Traws Pharma, Inc. has 16 Schedule 13D or 13G filings on record since 2025-09-19. 5 holders' latest filing reports 5% or more of common stock, par value $.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Traws Pharma, Inc. and the warning signs.

See Traws Pharma, Inc.'s free Snapshot Watch Traws Pharma, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Traws Pharma, Inc. and the records around it.

Traws Pharma, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
• Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
• Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)

Want the whole picture on Traws Pharma, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Traws Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Traws Pharma, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Traws Pharma, Inc. by CUSIP 68232V884 and gives its principal executive office as 12 Penns Trail, Newtown, PA 18940 (SCHEDULE 13G, 2026-08-14).

Purpose of Transaction (Item 4)

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-05; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Traws Pharma, Inc.

Who owns Traws Pharma, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Traws Pharma, Inc.: Orbimed Advisors LLC (11.9%, Schedule 13D/A, filed 2026-05-05), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-08-14), Ikarian Capital, LLC (9.5%, Schedule 13G/A, filed 2026-08-14), Chernett Jorey (6.8%, Schedule 13G, filed 2026-01-16) and Perceptive Advisors LLC (6.1%, Schedule 13G/A, filed 2026-05-15).

Who are the largest shareholders of Traws Pharma, Inc.?

By the share each holder's latest filing reports, the largest holders of Traws Pharma, Inc. on this page are Orbimed Advisors LLC (11.9%), Sirenia Capital Management LP (9.9%) and Ikarian Capital, LLC (9.5%).

When did Orbimed Advisors LLC buy into Traws Pharma, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-05-05, reporting 11.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Traws Pharma, Inc.

Swipe the table sideways to see every column.

Traws Pharma, Inc.: every filing and event

Tools for this story

Each opens in a new tab, filled in for Traws Pharma, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Traws Pharma, Inc. is mentioned again
• Find former Traws Pharma, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes